TY - JOUR T1 - Disease control in patients with psoriatic arthritis in real clinical practice in Spain: MiDAS study JO - Reumatología Clínica (English Edition) T2 - AU - Gratacós,Jordi AU - Pablos,José L. AU - de Miguel,Eugenio AU - Juanola,Xavier AU - Fernández-Carballido,Cristina AU - Ariza,Rafael AU - Terradas-Montana,Pau AU - Sastré,Carlos AU - Sanabra,Cristina SN - 21735743 M3 - 10.1016/j.reumae.2022.03.008 DO - 10.1016/j.reumae.2022.03.008 UR - https://reumatologiaclinica.org/en-disease-control-in-patients-with-articulo-S2173574323000357 AB - ObjectiveMiDAS study assessed the percentage of psoriatic arthritis (PsA) patients treated in routine clinical practice who achieved control of disease activity according to Disease Activity in Psoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA). MethodsObservational, non-interventional, cross-sectional, multicenter study conducted under conditions of routine clinical practice in 36 centers with outpatient rheumatology clinics in Spanish public hospitals. Patients included were adults (≥18 years) with ≥6 months PsA diagnosis according to classification for PsA (CASPAR) criteria and undergoing treatment ≥3 months. The main variable evaluated was the percentage of patients under remission and low disease activity, assessed through DAPSA and MDA. Results313 patients with PsA were included: 54.3% male; with mean age of 54.1±12.2 years and mean disease duration of 10.5±9.0 years. Mean C-reactive protein (CRP) serum levels were 4.9±7.3mg/L. At the study visit, 58.5% of patients were in monotherapy (17.6% biological and 40.9% non-biological) and 41.2% were receiving biological and non-biological therapy.59.4% of patients showed low disease activity (DAPSA≤14) and 19.8% were on remission (DAPSA≤4). Moreover, 51.4% of the patients reached an MDA status (≥5 MDA). ConclusionsAround 40% of PsA patients presented uncontrolled disease, highlighting the need to improve the management of these patients in clinical practice. ER -